Cytomegalovirus Retinitis Across the Immunosuppression Spectrum: A Contemporary Framework for Risk Stratification, Diagnosis, and Vision-Preserving Therapy
Open Access
- 25 September 2026
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7482
Abstract
Cytomegalovirus retinitis (CMVR) causes irreversible visual loss in patients with severe cellular immunodeficiency. Among people living with human immunodeficiency virus (HIV), risk is the highest with profound CD4+ T-cell depletion and absent or ineffective antiretroviral therapy. Other susceptible groups include transplant recipients, patients receiving treatment for malignancy or targeted immunosuppression, and children with inborn errors of immunity. This narrative review connects risk assessment, diagnosis, antiviral selection, and follow-up. Dilated retinal examination and serial imaging establish lesion activity and vision threat. Ocular-fluid polymerase chain reaction supports uncertain diagnoses, but results require interpretation alongside retinal findings and prior treatment. Antiviral selection requires concurrent assessment of lesion location, diagnostic certainty, renal function, marrow reserve, and systemic cytomegalovirus (CMV) disease. Systemic valganciclovir or ganciclovir provides the treatment backbone when feasible; immediately sight-threatening lesions may require adjunctive intravitreal therapy. Resistance or toxicity can necessitate alternatives, while evidence for newer agents remains limited. Maintenance duration depends on retinal inactivity and sustained immune recovery, with less certain stopping criteria outside HIV. Surveillance should address recurrence, immune recovery uveitis, retinal detachment, macular and vascular injury, and visual dysfunction beyond central acuity. Geographically diverse studies illustrate detection gaps, although heterogeneous populations and methods limit direct comparisons of burden and treatment outcomes.Keywords
Funding Information
- National Natural Science Foundation of China (82070213)
- National Natural Science Foundation of China (82370196)
This publication has 115 references indexed in Scilit:
- Seeing the Bigger Picture: Cytomegalovirus Retinitis Screening in Pediatric Hematopoietic Stem Cell Transplant PatientsPediatric Blood & Cancer, 2025
- Retinal detachment and mortality in patients with cytomegalovirus retinitis: A multicenter study in taiwanGraefe's Archive for Clinical and Experimental Ophthalmology, 2024
- Immune recovery uveitis: a focus reviewGraefe's Archive for Clinical and Experimental Ophthalmology, 2024
- ISCEV Standard for full-field clinical electroretinography (2022 update)Documenta Ophthalmologica, 2022
- ISCEV standard for clinical multifocal electroretinography (mfERG) (2021 update)Documenta Ophthalmologica, 2021
- Development of cytomegalovirus retinitis after negative conversion of cytomegalovirus antigenemia due to systemic antiviral therapyGraefe's Archive for Clinical and Experimental Ophthalmology, 2020
- Clinical features of cytomegalovirus retinitis after solid organ transplantation versus hematopoietic stem cell transplantationGraefe's Archive for Clinical and Experimental Ophthalmology, 2020
- The pathogenesis of human cytomegalovirusThe Journal of Pathology, 2014
- Clinical Manifestations of Cytomegalovirus-Associated Posterior Uveitis and Panuveitis in Patients Without Human Immunodeficiency Virus InfectionJAMA Ophthalmology, 2013
- Treatment of Cytomegalovirus Retinitis With an Intraocular Sustained-Release Ganciclovir ImplantArchives of Ophthalmology (1950), 1994